WallStSmart

Cibus Global LLC (CBUS)vsModerna Inc (MRNA)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Moderna Inc generates 51154% more annual revenue ($2.23B vs $4.35M). CBUS leads profitability with a 0.0% profit margin vs -141.4%. MRNA earns a higher WallStSmart Score of 21/100 (F).

CBUS

Avoid

18

out of 100

Grade: F

Growth: 6.7Profit: 2.5Value: 6.7Quality: 3.5
Piotroski: 3/9Altman Z: -4.95

MRNA

Avoid

21

out of 100

Grade: F

Growth: 2.7Profit: 2.0Value: 6.7Quality: 7.5
Piotroski: 3/9Altman Z: 2.09
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CBUSUndervalued (+88.0%)

Margin of Safety

+88.0%

Fair Value

$17.44

Current Price

$1.57

$15.87 discount

UndervaluedFair: $17.44Overvalued
MRNAUndervalued (+70.0%)

Margin of Safety

+70.0%

Fair Value

$134.97

Current Price

$143.97

$9.00 discount

UndervaluedFair: $134.97Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CBUS0 strengths · Avg: 0/10

No standout strengths identified

MRNA2 strengths · Avg: 9.0/10
Market CapQuality
$56.02B9/10

Large-cap with strong market position

Debt/EquityHealth
0.199/10

Conservative balance sheet, low leverage

Areas to Watch

CBUS4 concerns · Avg: 3.5/10
Price/BookValuation
8.3x4/10

Trading at 8.3x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$119.99M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

MRNA4 concerns · Avg: 3.3/10
Price/BookValuation
8.5x4/10

Trading at 8.5x book value

Revenue GrowthGrowth
2.1%4/10

2.1% revenue growth

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-46.6%2/10

ROE of -46.6% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : CBUS

CBUS has a balanced fundamental profile.

Bull Case : MRNA

The strongest argument for MRNA centers on Market Cap, Debt/Equity.

Bear Case : CBUS

The primary concerns for CBUS are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.21 is elevated, increasing financial risk.

Bear Case : MRNA

The primary concerns for MRNA are Price/Book, Revenue Growth, Piotroski F-Score.

Key Dynamics to Monitor

CBUS profiles as a value stock while MRNA is a turnaround play — different risk/reward profiles.

CBUS carries more volatility with a beta of 1.59 — expect wider price swings.

CBUS is growing revenue faster at 6.5% — sustainability is the question.

CBUS generates stronger free cash flow (-9M), providing more financial flexibility.

Bottom Line

MRNA scores higher overall (21/100 vs 18/100). CBUS offers better value entry with a 88.0% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cibus Global LLC

HEALTHCARE · BIOTECHNOLOGY · USA

Cibus Global, Ltd., a biotechnology company, develops plant traits for seed industry globally. The company is headquartered in San Diego, California.

Visit Website →

Moderna Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Moderna, Inc., a biotechnology company, develops messenger RNA-based vaccines and therapies for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and autoimmune diseases. The company is headquartered in Cambridge, Massachusetts.

Want to dig deeper into these stocks?